The nuclear factor-kB (NF-kB) is known to be activated in many cancer types including lung, ovarian, astrocytomas, melanoma, prostate as well as glioblastoma, and has been shown to correlate with disease progression. We have cloned a novel NF-kB-based reporter system (five tandem repeats of NF-kB responsive genomic element (NF; 14 bp each)) to drive the expression cassette for both a fusion between the yeast cytosine deaminase and uracil phosphoribosyltransferase (CU) as a therapeutic gene and the secreted Gaussia luciferase (Gluc) as a blood reporter, separated by an internal ribosomal entry site (NF-CU-IGluc). We showed that malignant tumor cells have high expression of Gluc, which correlates to high activation of NF-kB. When NF-kB was further activated by tumor necrosis factor-a in these cells, we observed up to 10-fold increase in Gluc levels and therefore transgene expression in human glioma cells served to greatly enhance the sensitization of these cells to the prodrug, 5-fluorocytosine both in cultured cells and in vivo subcutaneous tumor xenograft model. This inducible system provides a tool to enhance the expression of imaging and therapeutic genes for cancer therapy.
INTRODUCTION
Over the last decade, cancer gene therapy has been an evolving and promising field for cancer treatment. Many gene therapy strategies have or are still being tested in clinical trials in cancer patients. This therapeutic approach is based on the introduction of toxic elements into the tumor in a manner so as to achieve maximum toxicity specifically toward tumor cells while having a minimal effect on the surrounding normal cells. Among the toxic proteins used in gene therapy are: proapoptotic bax, 1 diphtheria toxin A, 2 tumor necrosis factor-a (TNFa 3 ) and many others. 4 One particular strategy for cancer gene therapy is the gene directed enzyme/prodrug therapy (for review see Both, 5 Connors, 6 Denny, 7 Khatri and Rusell 8 ), also referred to as 'suicide therapy' . In this therapeutic modality, an exogenous enzyme targeted for preferential expression in tumor cells converts a non-toxic prodrug into a potent toxin, leading to cell death. One of the commonly used enzyme/prodrug combination is herpes simplex thymidine kinase/ganciclovir. 9 Although proven efficient in many animal tumor models, this treatment modality requires cell contact via gap junctions to kill neighboring non-transduced tumor cells, which limits its extent of toxicity within the tumor mass. 10, 11 Another commonly used gene directed enzyme/prodrug therapy is the E. coli cytosine deaminase (CD) in combination with the prodrug 5-fluorocytosine (5-FC). [12] [13] [14] The bacterial CD converts 5-FC into the cytotoxic agent 5-FU, which is further transformed into the DNA and RNA damaging metabolites 5-fluorodeoxyuridine-5¢-monophosphate and 5-fluorouridine-5¢-triphosphate. 13 The pyrimidine analog 5-FU has been extensively studied and is used as a drug for cancer treatment including colorectal cancer. 15 E. coli uracil phosphoribosyltransferase (UPRT) has been shown to have synergistic anti-tumor effect with CD, as 5-FU generated through CD is further metabolized into 5-FUMP by UPRT. 16, 17 Further, the yeast forms of CD and UPRT have recently been shown to have enhanced toxicity to tumor cells as compared with the bacterial enzymes. 18, 19 The use of inducible promoters in suicidal gene therapy provides a selective control of transgene expression, thus yielding a safer delivery of toxic genes to tumors. The main challenge is the choice of a highly active promoter to ensure sufficient transgene expression with a maximal therapeutic benefit. Constitutive activation of the transcription factor nuclear factor-kB (NF-kB) is a common trait in malignant tumors. This transcription factor mediates inflammation-induced tumor growth and promotes the expression of prosurvival genes and inhibition of proapoptotic genes, thereby contributing to chemoresistance in malignant tumors. 20, 21 Further, many anti-cancer drugs activate NF-kB leading to enhanced chemoresistance. 22 As NF-kB is constitutively active in malignant tumors but not in normal tissue and its activation can be enhanced within the tumor and its environment by treatment modalities such as chemotherapy, 22 radiotherapy, 23 or by inflammatory and/or hypoxic conditions, 24 the use of an NF-kB-driven therapeutic gene has the potential to be both potent against tumors and safe for normal tissue.
Efficient cancer gene therapy depends on highly selective gene delivery with specific gene expression within the tumor. 25 Combining suicidal gene therapy with non-invasive imaging offers the advantage of assessing both transgene expression and tumor volume in vivo. Using the naturally secreted Gaussia luciferase (Gluc), we have developed a blood-based bioluminescent assay to monitor biological processes such as tumor growth and response to therapy as well as activation of transcription factors. [26] [27] [28] This assay allows non-invasive, real-time measurement of transgene activity by ex vivo quantification of the Gluc activity in a few microliters of blood samples over time in the same experimental animal.
In this study, we exploited the constitutive NF-kB activation in tumors as a way to achieve high transgene expression. We cloned a novel NF-kB-based promoter system (five tandem repeats of NF-kB responsive element (NF; 14 bp each) 26 ) to drive the expression of both a protein fusion between yeast CD and yeast UPRT (CU) as a therapeutic gene, and Gluc as a blood reporter separated by an internal ribosomal entry site (NF-CU-IGluc). We packaged this construct into a lentivirus vector and applied it for suicidal gene therapy in malignant tumor cells. TNFa was used to further activate NF-kB, which enhanced the killing effect of the prodrug 5-FC in NF-CU-IGluc-transduced cells in culture, as well as in an experimental subcutaneous tumor model in vivo.
RESULTS

NF-jB-controlled transgene expression
As NF-kB is constitutively active in cancer cells, we designed a reporter system in which we cloned into a lentivirus vector an NF-kBresponsive promoter (five tandem repeats of NF-kB responsive element (NF; 14 bp each) and a TATA box) to drive the expression of both the CU therapeutic fusion protein and the Gluc reporter separated by an internal ribosomal entry site (NF-CU-IGluc; Figure 1a ). To reduce any possible NF-kB-independent transactivation of transgene expression through the site of genomic insertion, we inserted two copies of the chicken b-globin cHS4 insulators in the U3 region of the lentivirus vector, therefore flanking the integrated provirus on both sides with the insulator. 26 On NF-kB activation, the Gluc is expressed and is secreted from cells, and therefore can be detected in the conditioned medium in culture or in the blood of animals ex vivo over time. The level of Gluc in blood correlates with the level of CU expression, thereby allowing us to indirectly monitor the therapeutic gene expression.
NF-jB is activated in malignant tumor cells Malignant and invasive tumor cells are known to have high NF-kB transcriptional activity as compared with normal cells. [29] [30] [31] [32] [33] [34] To confirm NF-kB activation in different tumor cell lines using our system, Gli36 and U87 human glioma cells, A549 lung adenocarcinoma cells, PC3 prostate adenocarcinoma cells, colo 320 colorectal adenocarcinoma cells as well as 293T immortalized human fibroblast cells transduced with lenti-NF-CU-IGluc were plated in a 96-well plate and treated with either phosphate-buffered saline (PBS; control) or TNFa. At 24 h later, aliquots of the conditioned medium were assayed for Gluc activity. Fibroblast cells (293T) showed the lowest levels of endogenous Gluc expression and the highest levels of NF-kB activated expression as compared with the other tumor cell lines tested that showed significantly higher endogenous Gluc levels confirming previous findings (Figure 1b ). Despite these higher levels of endogenous NF-kB promoter activation in malignant tumor cell lines, when cells were exposed to TNFa, NF-kB was further activated by up to fivefold in tumor cells compared with 425-fold in the 293T fibroblast cells, proving that our system is sensitive in monitoring both the basal NF-kB level as well as NF-kB activation in response to TNFa in tumors ( Figure 1b ). To investigate whether this increase in Gluc activity correlates with expression of the CU fusion, Gli36 glioma cells infected with lenti-NF-CU-IGluc were treated with either PBS or TNFa. At 24 h later, Gluc was assayed in the conditioned medium which showed approximately twofold increase in response to TNFa (Figure 1c ). At the same time, total RNA was extracted from these cells and the level of the CU fusion mRNA was analyzed by quantitative reverse transcriptase-PCR, which showed ninefold induction in CU fusion mRNA levels in response to TNFa (Figure 1d ).
In vitro effect of NF-jB-induced transgene expression
Gli36 human glioma cells stably expressing mCherry were infected with lenti-NF-CU-IGluc and plated in 96-well plate. At 48 h later, cells were treated with TNFa (2.5 ng ml À1 ) or PBS control. Gluc levels were measured 24 h later as a marker for CU transgene expression and showed a twofold induction in response to TNFa similar to the induction level shown in Figure 1c . Cells were then treated with either PBS (control) or 5-FC (50 mg ml À1 ) and at different time points, cell viability was assayed using an adenosine triphosphate-based biolumi- Gli36 human glioma cells stably expressing mCherry were infected with lenti-NF-CU-IGluc and plated in a 96-well plate. Cells were either treated with PBS, TNFa (2.5 ng ml À1 ), 5-FC (50 mg ml À1 ) or both TNFa+5-FC. At different time points, cell viability was assayed using an adenosine triphosphate-based cell-titer Glo assay (a) and was confirmed by mCherry analysis using fluorescent microscopy (b). Scale bar, 100 mm. (c) Gli36 cells expressing CU under the control of CMV promoter (CMV-CU) or CU under no promoter (control vector) were treated as described in a and b. Cell viability was assayed 48 h later using cell-titer Glo. (d) Gli36 cells transduced with lenti-NF-CU-IGluc were treated as above. At 48 h later, cells were stained for PI and Annexin V-FITC and subjected to flow cytometry analysis. (e) U87, A549, PC3 and colo320 cells were transduced with lenti-NF-CU-IGluc and treated with TNFa and/or 5-FC as above. Cell viability was assayed 48 h later. *Pp0.05, **Pp0.001 Student t-test.
In vivo suicidal gene therapy in an NF-jB-controlled tumor environment To evaluate the therapeutic effect of transgene expression controlled by NF-kB activation in vivo, Gli36 cells stably expressing Fluc were infected with lenti-NF-CU-IGluc and implanted subcutaneously into nude mice. At 1 week later, mice were divided into two groups receiving either PBS or TNFa (20 mg per kg body weight). At 17 h after TNFa injection, 5 ml of blood were assayed for Gluc activity which showed 410-fold increase in Gluc level and therefore NF-kB activation and CU expression, as compared with PBS-treated mice (Figure 3a) . Each group of mice was then divided into two subgroups, which received either PBS or 5-FC (500 mg kg À1 ). Tumor growth was monitored by Fluc in vivo bioluminescence imaging once a week. Control tumors treated with PBS or TNFa alone showed similar exponential growth, demonstrating that the dose of TNFa used was not toxic to tumor cells. Tumors in mice treated with 5-FC alone showed a significantly reduced rate of growth as compared with PBS or TNFa. On the other hand, tumors in mice that received both TNFa+5-FC regressed within 2 weeks after injection (Figures 3b  and c) . In this group, tumors in 440% of mice (two out of five mice) completely regressed and did not show re-growth for 40 days. Tumors in the other mice slowly re-grew by 27 days after treatment. On re-induction of NF-kB activation and transgene expression with TNFa and treatment with 5-FC, tumor growth in these latter mice slowed down again showing that this NF-kB-controlled transgene expression can be re-activated in these tumors (data not shown).
To apply this therapeutic modality to a clinically relevant model, tumors expressing Fluc were generated in nude mice. At 3 weeks later, mice received an intra-tumoral injection of either lenti-NF-CU-IGluc or PBS (control). At 2 days after virus injection, mice were treated with intraperitoneally (i.p.) injections of either TNFa and/or 5-FC as above. Mice that received an intra-tumoral injection of lenti-NF-CUIGluc and treated with TNFa and 5-FC showed a clear delay in tumor growth as compared with mice treated with TNFa or PBS alone (Figures 3d and e) . Mice received the lenti-NF-CU-IGluc and treated with 5-FC alone also showed slower tumor growth but to a much lesser extent than the combined TNFa+5-FC-treatment. On the other hand, there was no significant difference among the four treated groups in tumors that received intra-tumoral injection of PBS indicating that neither 5-FC nor TNFa treatment affected tumor growth in the absence of the CU transgene expression (Figure 3e ).
DISCUSSION
Despite all progress in cancer gene therapy, improved targeted expression of toxic transgenes is still highly desirable. Since the implementation of gene directed enzyme/prodrug therapy, a vast leap toward this goal has been accomplished. The use of constitutively active promoters to drive the expression of toxic genes is advantageous, as strong transgene activity is required for an efficient therapeutic benefit. Nevertheless, these types of promoters could be rendered harmful toward normal tissues surrounding the tumor. Making use of the environment within the tumor to drive the expression of therapeutic genes provides a safer strategy for gene therapy. As NF-kB is upregulated and activated in malignant tumor, but not in normal tissues, the use of promoters responsive to this transcription factor activation provides a safe and potent therapeutic strategy.
Co-expression of cytosine deaminase and uracil phosphoribosyltransferase (CU) has been shown to have a significant synergistic effect toward the conversion of 5-FC into toxic metabolites. 17 In this study, Figure 3 In vivo suicidal gene therapy in an NF-kB-controlled tumor environment. (a-c) Gli36-Fluc human glioma cells were infected with lentivirus vector expressing NF-CU-IGluc and implanted subcutaneously in nude mice. At 1 week later, mice were divided into two groups, which received PBS or TNFa (20 mg per kg body weight). At 17 h after TNFa injection, 5 ml of blood was assayed for Gluc activity (a). Each group was then split into two subgroups, which received either PBS or 5-FC (500 mg kg À1 ). Tumor growth was monitored by Fluc in vivo bioluminescence imaging once a week after i.p. injection of D-luciferin. Photons count in the tumor was calculated using CMIRimage program and presented as % Fluc activity, in which the signal before injection was set to 100% (b). Bioluminescent images overlayed to bright field images at day 7 and 27 after implantation (c). Suicidal gene therapy in an NF-jB-controlled tumor CE Badr et al we evaluated NF-kB-driven expression of the fused CU gene as a targeted and tumor environment-controlled suicidal gene therapy. We showed that malignant tumor cells have constitutively active NF-kB, which led to slower tumor growth of cells transduced with CU on treatment with the prodrug 5-FC. Interestingly, further induction of NF-kB activation in vivo with TNFa yielded complete tumor regression in 440% of mice. As our reporter system also drives the expression of the secreted Gluc under NF-kB responsive elements, the Gluc blood level served as a sensitive marker for basal and extrinsic NF-kB activation, and therefore therapeutic gene expression in the tumor. We observed a much higher increase in Gluc expression, and therefore NF-kB activation, in Gli36 human glioma subcutaneous tumors in vivo as compared with the same cells in culture. We hypothesized that TNFa injection in mice could also stimulate the recruitment of other cytokines and NF-kB inducing factors to the tumor therefore contributing further toward NF-kB activation. NF-kB can be induced not only by cytokines, such as TNFa, but also by factors within the tumor environment, such as hypoxia 24 and inflammation. 22 Additional extrinsic factors commonly used in cancer therapy could potentially induce NF-kB activity. Ionizing radiation 23 as well as many chemotherapeutic drugs such as cisplatin, 35 doxorubicin, 36 taxol 37 gemcitabine, 38 and etoposide 39 are potent inducers of NF-kB activation. These therapeutic modalities could be easily applied to our inducible gene therapy system to achieve a targeted and more efficient transgene expression.
One challenge in suicidal gene therapy is the need to achieve high transduction efficiency at the tumor site. Given that only a small percentage of cells in the tumor mass express the transgene following viral vector delivery, usually about 1-5% after direct intratumoral injection, 40 it is essential that the transgene product has a 'bystander' effect, such that adjacent, uninfected tumor cells are also killed. Unlike the herpes simplex virus thymidine/ganciclovir kinase system, which requires gap junctions in order to kill non-transduced cells, the 5-FU diffuses freely between cells in the absence of gap junctions. 41 A transduction efficiency as low as 1% by an adenovirus expressing CD and UPRT has been reported to impact tumor growth. 17 In this study, we tried to address this issue by testing our lentivirus system injected directly into tumors. Although the therapeutic effect was less dramatic than the one observed in tumor xenografts transduced with the lentivirus ex vivo, there was a significant delay in tumor growth in mice treated with both TNFa and 5-FC as compared with the control group. The NF-CU-IGluc expression cassette could be cloned into any viral vector known to transduce tumor cells more efficiently, such as adenovirus, adeno-associated virus or herpes virus vectors, which might achieve a more pronounced effect on tumor growth.
Optimization of gene therapy can be facilitated by imaging methods that provide a means to monitor levels, cell specificity and duration of transgene expression, as well as tumor growth and regression. 42, 43 Several efforts have been made toward non-invasive imaging of gene expression using techniques such as fluorescence, bioluminescence, magnetic resonance and positron emission tomography. [44] [45] [46] Positron emission tomography and magnetic resonance imaging have the advantage over optical imaging in that they can be translated into clinical use. However, for pre-clinical evaluation, these methods are costly and not very sensitive. Recently, Xing et al. 47 developed a CD and CU fusion gene with a monomeric red fluorescent protein. This reporter enabled them to monitor transgene expression and prodrug activation using optical fluorescence imaging of red fluorescent protein and magnetic resonance spectroscopy with fluorine-19. One drawback of magnetic resonance spectroscopy is the lack of sensitivity when applied to small animals. Fluorescence imaging is also rendered difficult and lacks sensitivity because of autofluorescence. Bioluminescence imaging is more sensitive, however, similar to fluorescence, quantification of the signal can be compromised by the location, especially in deep tissues and blood (hemoglobin)-rich organs, such as the liver, spleen and bone marrow because of photon absorption, which can result in an underestimation of transgene expression. 48 Using secreted reporters in the blood, such as the Gluc, can help to overcome these problems and provide a sensitive and quantitative assessment of gene expression in real-time 27, 28 .
In addition to being an adjunct therapy for many types of malignant tumors, the NF-CU-IGluc system may also prove effective in shrinking benign tumors in inoperable locations, such as meningiomas or schwannomas pressing, on critical neural structures. 49 As these tumors are known to have low NF-kB activation, gene expression can be enhanced by activating this transcription factor using cytokines as described here or many other chemotherapeutic agents. This study provides a new and valuable tool for a safer and controlled gene therapy, whereas being able to non-invasively monitor therapeutic gene expression in real-time as a mean to evaluate different gene/drug therapies.
MATERIALS AND METHODS
Cell culture
Human kidney fibroblasts (293T) cells (from Dr Michele Calos, Stanford University, Stanford, CA, USA), Gli36 human glioma cells (from Dr Anthony Capanogni, UCLA, Los Angeles, CA, USA), U87 human glioma cells, PC3 prostate adenocarcinoma cells, colo 320 colorectal adenocarcinoma cells and A549 human lung carcinoma cells (from American Type Culture Collection, Rockville, MD, USA) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Sigma, St Louis, MO, USA), 100 U ml À1 penicillin, and 0.1 mg ml À1 streptomycin (Sigma). Cells were maintained in a 5% CO 2 humidified incubator at 37 1C.
Lentivirus vector constructs
We used the CSCW-IG, a self-inactivating lentivirus vector in which we have replaced the CMV promoter with five tandem repeats of the NF-kB transcription responsive elements (5¢-TGGGGACTTTCCGC-3¢) along with a TATA box serving as a minimal promoter to drive the expression of the CD-UPRT fusion as well as Gluc complementary DNA, separated by an internal ribosomal entry site element. 26 In this construct, we also inserted a DNA fragment spanning two copies of the 1.2 Kb chicken b-globin (HS4) insulator elements, amplified from the pJC13-1 plasmid (a kind gift of Dr Adam West, National Institutes of Health, Bethesda, MD, USA), 50 into the U3 region of this lentivirus vector to retain minimal nonspecific transcription of gene expression as previously described. 26 The synthetic fusion between yeast CD and UPRT commercially referred to as fcy::fur (Invivogen, San Diego, CA, USA) was obtained by PCR using the pORF5-fcy::fur plasmid as a template. Gluc, codon optimized for mammalian gene expression was amplified by PCR from pHGC-humGluc. 51 This plasmid identified as csw-NF-CD-UPRT-IGluc was packaged into a lentivirus vector as described previously. 52 The lentivirus vector is referred to as lenti NF-CU-IGluc. The NF transcription responsive elements were replaced by a CMV promoter to generate csw-CMV-CD-UPRT-IGluc. To general a negative control vector, which lacks a promoter, the NF transcription responsive elements were removed from the csw-NF-CD-UPRT-Igluc, thereby generating a csw-CD-UPRT-IGluc vector. The lenti-mCherry is a lentivirus vector expressing mCherry under the control of a CMV promoter. In all experiments, cells were transduced with the lentivirus vectors at a multiplicity of infection of 100 transduction units per cell to achieve stable transduction of 490% of cells.
In vitro luciferase assays
For Gluc assays, 20 ml aliquots of the cell-free conditioned medium were collected in a new white 96-well plate at different time points. Gluc activity was assayed by adding 20 mM coelenterazine, the Gluc substrate (Nanolight, Pinetop, AZ, USA) and measuring photon counts over 10 s using a 96-well plate luminometer (Dynex, Richfield, MN, USA).
Quantitative reverse transcriptase-PCR
Cells transduced with lenti-NF-CU-IGluc were plated in a six-well plate and treated with 0 or 10 ng ml À1 of TNFa (R&D systems, Minneapolis, MN, USA). After 24 h, total RNA was isolated using the RNeasy mini kit (Qiagen, Valencia, CA, USA) and complementary DNA was generated using Omniscript reverse transcription kit (Qiagen). Real-time PCR was performed in an ABI PRISM 7000 Sequence Detection System Thermal Cycler (Applied Biosystems, Carlsbad, CA, USA). The following primer sets were used: 5¢-TGTGGTGGG AGAGAATGTCA-3¢; 5¢-AAACCAGTCCTGGGGTCTCT-3¢ and 5¢-ATTTGT GGGGTGTCCATTGT-3¢; 5¢-GCAGTCTCCTCATCCCTCTG-3¢ amplifying sequences in the CD and UPRT regions, respectively. The fold increase was calculated based on Ct values of TNFa-treated cells relative to untreated. Human glyceraldehyde 3-phosphate dehydrogenase mRNA expression was used for normalization.
In vitro analysis of tumor therapy
Gli36 cells were transduced with lenti-NF-CU-IGluc or lenti-mCherry at a multiplicity of infection of 100. At 2 days after transduction, cells were plated in a 96-well plate at low density (1000 cell per well) and treated with or without TNFa (2.5 ng ml À1 ). After 24 h, 5-FC (Sigma; 250 mg ml À1 ) was added to the cells. Viability assays were measured 5 days after 5-FC treatment. For cytotoxicity assays, we used the cell-titer glo (Promega, Madison, WI, USA) according to the manufacturer's guidelines. Data was calculated as percentage of cell viability. Fluorescence images of cells stably expressing mCherry were captured using an inverted fluorescent microscope (Nikon TE 200-U, Tokyo, Japan) coupled to a digital camera. Alternatively, cell death was measured with flow cytometry by staining for annexin V-PI. Gli36-NF-CU-IGluc cells were plated in six-well plates (150 000 cell per well). After 24 h cells were treated with 0 or 2.5 ng ml À1 of TNFa for 16 h followed by a 48 h treatment with 5-FC (250 mg ml À1 ). Single-cell suspensions were stained with CytoGLO Annexin V-FITC Apoptosis Kit (Imgenex, San Diego, CA, USA) and subjected to flow cytometry using a BD FACS caliber flow cytometer (BD biosciences, Woburn, MA, USA).
Animal experiments
All animal experiments were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care. Gli36-Fluc cells were transduced with Lenti-NF-CU-IGluc or Lenti-Fluc-mCherry. One million of these cells (in 50 ml PBS) were mixed with 50 ml Matrigel and implanted subcutaneously into nude mice (4-5 weeks of age). At 1 week after implantation, tumor volume was monitored using Fluc bioluminescence imaging (as described below). Mice were then separated into four different groups of five mice. Each group was injected i.p. with PBS, 5-FC (500 mg per kg body weight), TNFa (20 mg kg À1 ) or the same amounts of both 5-FC and TNFa. PBS or 5-FC injections were repeated twice daily for 12 consecutive days. Mice receiving TNFa were injected i.p. once every 3 days during these 12 days. The first daily 5-FC dose was administered 17 h following TNFa injection. Immediately before and 17 h after TNFa injection, 5 ml of blood was withdrawn from each mouse and assayed for Gluc activity, a marker for NF-kB activation and therefore transgene expression (see below). In another experiment, Gli36 cells expressing Fluc-mCherry were implanted subcutaneously into 32 nude mice. At day 19, mice were randomly divided into four groups of eight mice, which were divided into two subgroups: (1) received intra-tumoral injection of lenti-NF-CU-IGluc (10 7 transducing units in 5 ml); (2) received 5 ml PBS. These injections were repeated 24 h later. Treatment with TNFa and/or 5-FC started at day 21 and lasted for 14 days as described above.
Gluc blood assay
Blood (5 ml) was collected by making a small nick in the mouse tail and mixed immediately with 1 ml 20mM EDTA. Gluc activity was measured using the luminometer after injecting 100 ml 100 mM coelenterazine and acquiring photon counts over 10 s.
In vivo Fluc bioluminescence imaging
Mice were anesthetized by i.p. injections of ketamine (100 mg kg À1 ) and xylazine (5 mg kg À1 ) and then received an i.p. injection of D-luciferin (150 mg kg À1 body weight diluted in PBS). Photon counts were acquired for 1-5 min using a cooled charge-coupled device (CCD) camera system. Light surface images were also taken before each imaging session providing an anatomical view of the animal. Image processing and signal intensity quantification and analysis were performed using CMIR-Image, software developed by the Center for Molecular Imaging Research at Massachusetts General Hospital using image display and analysis suite developed by IDL (Research Systems Inc., Boulder, CO, USA). Images were represented in a pseudo-color photon count manner, superimposed on a gray-scale anatomic white-light image, exposing the bioluminescence intensity as well as the animal anatomy. Bioluminescence signals were defined by an automatic intensity highlight procedure after subtracting background noise. The sum of the photon counts was calculated as a measure of Fluc reporter activity.
